Cervical cancer rates are 87% lower in women who have had the Cervarix HPV vaccine between the ages of 12-13, according to a new study by The Lancet.
The study also found a 62% reduction in the disease in women who got the vaccine between the ages 14-16.
The study further found a 34% reduction in women who got the vaccine aged 16-18.
The study began in England in 2008.
The Lancet said that “this is the first direct evidence of prevention of cervical cancer using the bivalent vaccine, Cervarix.”
Gardasil 9 is the vaccine currently used in Ireland, which protects against 9 out of 10 cervical cancers.
Immunisation in schools in Ireland was extended to boys in 2019, who can develop other cancers from the virus.
Dr. Kate Soldan from the UK Health Security Agency said: “This represents an important step forwards in cervical cancer prevention.”
“We hope that these new results encourage uptake as the success of the vaccination programme relies not only on the efficacy of the vaccine but also the proportion of the population vaccinated.”
IMAGE – “201214-D-BN624-0811” (CC BY 2.0) by U.S. Secretary of Defense